Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells

Aylin Orhaner, Mehmet Cudi Tuncer, İlhan Özdemir

Open source

DOI
10.3390/ph19081154
Published
2026-07-24
Container
Pharmaceuticals
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ph19081154,
  title = {Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells},
  author = {Aylin Orhaner and Mehmet Cudi Tuncer and İlhan Özdemir},
  year = {2026},
  journal = {Pharmaceuticals},
  doi = {10.3390/ph19081154},
  url = {https://doi.org/10.3390/ph19081154}
}

RIS

TY  - JOUR
TI  - Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells
AU  - Aylin Orhaner
AU  - Mehmet Cudi Tuncer
AU  - İlhan Özdemir
PY  - 2026
JO  - Pharmaceuticals
DO  - 10.3390/ph19081154
UR  - https://doi.org/10.3390/ph19081154
ER  - 

APA

Orhaner, A., Tuncer, M. C., & Özdemir, İ. (2026). Thymoquinone Potentiates Docetaxel-Induced Antitumor Activity with the Involvement of ROS and PI3K/AKT Pathway Modulation in Triple-Negative Breast Cancer Cells. Pharmaceuticals. https://doi.org/10.3390/ph19081154

Source records